Immunogenicity of Fractional-Dose Vaccine during a Yellow Fever Outbreak — Final Report

• Published in: The New England journal of medicine Vol. 381; no. 5; pp. 444 - 454
• Main Authors: Casey, Rebecca M, Harris, Jennifer B, Ahuka-Mundeke, Steve, Dixon, Meredith G, Kizito, Gabriel M, Nsele, Pierre M, Umutesi, Grace, Laven, Janeen, Kosoy, Olga, Paluku, Gilson, Gueye, Abdou S, Hyde, Terri B, Ewetola, Raimi, Sheria, Guylain K.M, Muyembe-Tamfum, Jean-Jacques, Staples, J. Erin
• Format: Journal Article
• Language: English
• Published: United States Massachusetts Medical Society 01.08.2019
• Subjects: Adolescent; Adult; Age; Antibodies, Neutralizing - blood; Antibodies, Viral - blood; Child; Child, Preschool; Democratic Republic of the Congo - epidemiology; Disease control; Disease Outbreaks; Disease prevention; Female; Fever; Follow-Up Studies; Health surveillance; Humans; Immune response; Immunogenicity; Male; Medical laboratories; Middle Aged; Outbreaks; Public health; Seroconversion; Vaccination; Vaccines; Womens health; Yellow Fever - epidemiology; Yellow Fever - immunology; Yellow Fever - prevention & control; Yellow Fever Vaccine - administration & dosage; Yellow Fever Vaccine - immunology; Yellow fever virus - immunology; Yellow fever virus - isolation & purification; Young Adult; Democratic Republic of the Congo; Angola; Congo-Democratic Republic of Congo; United States > US; Africa

To counter a limited global supply of yellow fever vaccine, the use of a fractional dose of vaccine (one fifth of the standard dose) during an outbreak in the Democratic Republic of Congo resulted in immunogenicity consistent with expected protective titers at 1-month and 1-year follow-up.